Conmed (NYSE:CNMD) Azioni

CONMED CORP

Conmed

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Conmed Corp

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Mike Matson downgraded the rating for CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Buy to Hold and maintained the price target of $61. Conmed shares closed at $56.95 on Wednesday. <a href="https://www.benzinga.com/quote/CNMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Bryan Spillane downgraded Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Neutral to Underperform and lowered the price target from $27 to $20. Conagra Brands shares closed at $22.37 on Wednesday. <a href="https://www.benzinga.com/quote/CAG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) from Buy to Neutral and raised the price target from $14 to $18. Venture Global shares closed at $16.76 on Wednesday. <a href="https://www.benzinga.com/quote/VG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CAG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CAG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12084536/image-194-1024x571.png" alt="" class="wp-image-947616" style="width:549px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12084536/image-194-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12084536/image-194-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12084536/image-194-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12084536/image-194.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

CNMD

GENI

This Conagra Brands Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

During the last three months, 5 analysts shared their evaluations of Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Conmed and provided 12-month price targets. The average target is $58.4, accompanied by a high estimate of $61.00 and a low estimate of $55.00. This current average has decreased by 20.44% from the previous average price target of $73.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1749733245_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Conmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$58.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Conmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Conmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Conmed's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Conmed analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Conmed</h2>
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East &amp; Africa, Asia Pacific and North America. Majority is revenue is from USA.
<h3>Conmed: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Conmed displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 2.88%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Conmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.62%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Conmed's ROA stands out, surpassing industry averages. With an impressive ROA of 0.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.91, Conmed adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Conmed: Insights From 5 Analyst Reviews

Needham analyst Mike Matson downgrades Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Buy to Hold and maintains the price target from $61 to $61.

Price Target

Needham Downgrades Conmed to Hold, Maintains Price Target to $61

Management

CONMED Appoints Laverne Council To Succeed Martha Goldberg Aronson As Independent Chair Of The Board Of Directors, Effective May 21, 2025

JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Neutral and lowers the price target from $70 to $58.

JP Morgan Maintains Neutral on Conmed, Lowers Price Target to $58

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Thursday.
Shares of CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose sharply during Thursday's session after the company reported better-than-expected first-quarter results and <a href="https://www.benzinga.com/quote/CVS/earnings">raised FY25 EPS guidance</a>.
CVS Health reported first-quarter sales of $94.59 billion on Thursday, beating the consensus of $93.64 billion. Total revenues increased 7% year over year, driven by revenue growth across all segments.
CVS Health posted adjusted EPS of $2.25 for Q1, a sharp rise from $1.31 a year earlier and well above Wall Street&#8217;s $1.70 estimate.
CVS Health shares jumped 6.5% to $71.11 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Cantor Equity Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) surged 28% to $53.98.</li>
<li>E2open Parent Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NASDAQ">ETWO</a>) shares jumped 26.4% to $2.4901.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) gained 24.4% to $4.6550 following better-than-expected quarterly earnings.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) rose 19.7% to $10.06 following strong quarterly sales.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) gained 19.6% to $1.9500.</li>
<li>Advanced Energy Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) rose 16.7% to $113.72 after the company reported better-than-expected first-quarter financial results and issued second-quarter sales guidance above estimates. Additionally, Needham maintained a Buy rating on the stock and Baird maintained an Outperform rating.</li>
<li>MYR Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) gained 16.2% to $142.09 following upbeat quarterly earnings.</li>
<li>CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) rose 16.1% to $57.01 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 15.3% to $47.60.</li>
<li>Chart Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) rose 14.2% to $154.11 after the company reported better-than-expected first-quarter adjusted EPS results and issued FY25 adjusted EPS guidance above estimates. Also, the company issued FY25 sales guidance with its midpoint above estimates.</li>
<li>TTM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) gained 13.4% to $22.70 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
<li>Frontdoor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) rose 13.3% to $46.56 after the company reported better-than-expected first-quarter financial results and raised tis FY25 sales guidance above estimates.</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) gained 12.4% to $329.11 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance with its midpoint above estimates.</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) rose 12% to $60.87 after the company reported better-than-expected quarterly financial results and raised its FY25 adjusted EPS guidance.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) gained 10.4% to $69.07 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) rose 9.7% to $93.67.</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) gained 9.6% to $433.29 following strong quarterly earnings.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) rose 8.2% to $137.75.</li>
<li>CNH Industrial N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) gained 8.2% to $12.52 following quarterly results.</li>
<li>Comfort Systems USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) jumped 7.4% to $427.31.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) gained 6.4% to $260.16.</li>
<li>Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) rose 6.2% to $119.61 following upbeat results.</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) gained 5.6% to $580.00 following strong quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45135511/how-to-earn-500-a-month-from-apple-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Apple Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Movers

AEIS

CARR

COMM

CRWV

CVNA

ETWO

FTDR

GTLS

MSFT

MYRG

TTMI

CVS Health Posts Better-Than-Expected Earnings, Joins CommScope, Microsoft, Meta, Chart Industries, And Other Big Stocks Moving Higher On Thursday

Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $70 to $57.

Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $57

WIIM

Conmed shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance.

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 68.2% to $4.81 during Thursday's pre-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 36.2% to $0.02. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 28.98% to $0.89. The market value of their outstanding shares is at $5.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock moved upwards by 11.56% to $3.28. The market value of their outstanding shares is at $123.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares moved upwards by 10.63% to $1.55. The company's market cap stands at $48.5 million. </li>
<li>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) stock increased by 10.42% to $54.23. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) stock fell 31.3% to $6.61 during Thursday's pre-market session. The market value of their outstanding shares is at $454.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) stock decreased by 16.71% to $10.77. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q1 earnings report came out today. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 14.65% to $2.68. The market value of their outstanding shares is at $12.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 12.08% to $0.4. The market value of their outstanding shares is at $1.8 million. </li>
<li>Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) stock decreased by 11.72% to $6.78. The market value of their outstanding shares is at $2.0 billion. The company's, Q1 earnings came out today. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock fell 10.9% to $9.0. The company's market cap stands at $119.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

ADIL

ARVN

BCDA

FOLD

GLSI

LGMK

NAOV

SERA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

In the preceding three months, 6 analysts have released ratings for Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $70.33, a high estimate of $91.00, and a low estimate of $55.00. Highlighting a 14.58% decrease, the current average has fallen from the previous average price target of $82.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1746100830_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Conmed by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Conmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Conmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Conmed's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Conmed analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Conmed</h2>
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East &amp; Africa, Asia Pacific and North America. Majority is revenue is from USA.
<h3>Understanding the Numbers: Conmed's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Conmed's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.78% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.76%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Conmed's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Conmed's ROA stands out, surpassing industry averages. With an impressive ROA of 1.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Conmed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.94.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Conmed: 6 Analysts Share Their Views

Needham analyst Mike Matson maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and lowers the price target from $91 to $61.

Needham Maintains Buy on Conmed, Lowers Price Target to $61

Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.81 by 17.28 percent. This is a 20.25 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $321.30 million which beat the analyst consensus estimate of $313.37 million by 2.53 percent. This is a 2.89 percent increase over sales of $312.27 million the same period last year.

Earnings Beats

CORRECTION: Conmed Q1 Adj. EPS $0.95 Beats $0.81 Estimate, Sales $321.30M Beat $313.37M Estimate

Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) raises FY2025 Adj EPS guidance from $4.25-$4.40 to $4.45-$4.60 vs $4.34 analyst estimate. Raises FY2025 sales outlook from $1.34 billion-$1.37 billion to $1.35 billion-$1.38 billion vs $1.36 billion estimate.

Guidance

Conmed Raises FY2025 Adj EPS Guidance from $4.25-$4.40 to $4.45-$4.60 vs $4.34 Est; Raises FY2025 Sales Guidance from $1.34B-$1.37B to $1.35B-$1.38B vs $1.36B Est

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Stifel analyst Rick Wise downgrades Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Buy to Hold and lowers the price target from $75 to $55.

Stifel Downgrades Conmed to Hold, Lowers Price Target to $55

Throughout the last three months, 4 analysts have evaluated Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $76.5, a high estimate of $91.00, and a low estimate of $70.00. Highlighting a 6.71% decrease, the current average has fallen from the previous average price target of $82.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738875615_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Conmed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Conmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Conmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Conmed's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Conmed analyst ratings.</a>
<h2>All You Need to Know About Conmed</h2>
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
<h3>Understanding the Numbers: Conmed's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Conmed's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 3.98%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Conmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.47% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.4%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Conmed's ROA excels beyond industry benchmarks, reaching 2.13%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.01.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Conmed: 4 Analysts Share Their Views

Stifel analyst Rick Wise maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Buy and raises the price target from $72 to $75.

Stifel Maintains Buy on Conmed, Raises Price Target to $75

Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $74 to $70.

Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $70

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Shweta Khajuria downgraded the rating for Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Outperform to In-Line and maintained the price target of $35. Match Group shares closed at $33.58 on Wednesday. <a href="https://www.benzinga.com/quote/MTCH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Vijay Rakesh downgraded Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) from Outperform to Neutral and lowered the price target from $105 to $62. Skyworks Solutions shares closed at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Robbie Marcus downgraded CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Overweight to Neutral and cut the price target from $85 to $70. Conmed shares closed at $74.00 on Wednesday. <a href="https://www.benzinga.com/quote/CNMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Craig Ellis downgraded the rating for FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) from Buy to Neutral and lowered the price target from $64 to $34. FormFactor shares closed at $41.12 on Wednesday. <a href="https://www.benzinga.com/quote/FORM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Alex Scott downgraded Voya Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) from Overweight to Equal-Weight and maintained the price target of $75. Voya Financial shares closed at $72.22 on Wednesday. <a href="https://www.benzinga.com/quote/VOYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MTCH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-1024x576.png" alt="" class="wp-image-769131" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06063625/image-54.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

Pre-Market Outlook

MTCH

SWKS

VOYA

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) posted better-than-expected earnings for its fourth quarter, but issued FY25 <a href="https://www.benzinga.com/quote/CNMD/earnings">earnings and revenue guidance below estimates.</a>
Conmed reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 per share. The company reported quarterly sales of $345.94 million which beat the analyst consensus estimate of $341.01 million.
&#8220;2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability,&#8221; commented Patrick J. Beyer, CONMED&#8217;s President and Chief Executive Officer. &#8220;In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.&#8221;
Conmed said it sees FY2025 adjusted EPS of $4.25-4.40, versus market estimates of $4.74. The company expects sales of $1.344 billion-1.372 billion, versus projections of $1.40 billion.
Conmed shares gained 1.5% to close at $74.00 on Wednesday.
These analysts made changes to their price targets on Conmed following earnings announcement.
<ul>
<li>JP Morgan analyst Robbie Marcus downgraded Conmed from Overweight to Neutral and lowered the price target from $85 to $70.</li>
<li>Needham analyst Mike Matson maintained Conmed with a Buy and lowered the price target from $97 to $91..</li>
</ul>
Considering buying CNMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-1024x595.png" alt="" class="wp-image-769181" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06065648/image-55.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

These Analysts Slash Their Forecasts On Conmed After Q4 Results

Press Releases

CONMED Corporation Announces Quarterly Cash Dividend

CONMED Corporation to Present at the J.P. Morgan Healthcare Conference

CONMED Corporation to Announce Fourth Quarter 2024 Financial Results on February 5, 2025

CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

CONMED Corporation Adds Mark Kaye to its Board of Directors

CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025

Comments

Conmed

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO